ES2672472T3 - Composición farmacéutica que comprende ivabradina amorfa - Google Patents

Composición farmacéutica que comprende ivabradina amorfa Download PDF

Info

Publication number
ES2672472T3
ES2672472T3 ES14792774.3T ES14792774T ES2672472T3 ES 2672472 T3 ES2672472 T3 ES 2672472T3 ES 14792774 T ES14792774 T ES 14792774T ES 2672472 T3 ES2672472 T3 ES 2672472T3
Authority
ES
Spain
Prior art keywords
pharmaceutically acceptable
ivabradine
cyclodextrin
composition according
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14792774.3T
Other languages
English (en)
Spanish (es)
Inventor
Jacobus Theodorus Henricus EUPEN VAN
Rolf Keltjens
Deepak Murpani
Sonia García Jiménez
Lisardo ÁLVAREZ FERNÁNDEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Application granted granted Critical
Publication of ES2672472T3 publication Critical patent/ES2672472T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES14792774.3T 2013-12-12 2014-10-21 Composición farmacéutica que comprende ivabradina amorfa Active ES2672472T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
WOPCT/EP2013/076429 2013-12-12
EP2013076429 2013-12-12
PCT/EP2014/072524 WO2015001133A1 (fr) 2013-12-12 2014-10-21 Composition pharmaceutique comprenant de l'ivabradine amorphe

Publications (1)

Publication Number Publication Date
ES2672472T3 true ES2672472T3 (es) 2018-06-14

Family

ID=51845386

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14792774.3T Active ES2672472T3 (es) 2013-12-12 2014-10-21 Composición farmacéutica que comprende ivabradina amorfa

Country Status (3)

Country Link
ES (1) ES2672472T3 (fr)
MX (1) MX363389B (fr)
WO (1) WO2015001133A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015145234A1 (fr) * 2014-03-27 2015-10-01 Laboratorio Chimico Internazionale S.P.A. Adsorbats d'ivabradine
GB201621771D0 (en) * 2016-12-20 2017-02-01 Biogena (A P I) Ltd New salts of compounds and uses thereof
EP3366282A1 (fr) * 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions pharmaceutiques orales solides d'ivabradine
TR201703066A2 (tr) * 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
CN109875969B (zh) * 2019-03-19 2021-02-09 扬子江药业集团北京海燕药业有限公司 一种稳定的盐酸伊伐布雷定片剂及其制备方法
CN115770248B (zh) * 2022-12-07 2023-08-04 郑州大学第一附属医院 一种盐酸伊伐布雷定制剂及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868777B1 (fr) 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
PT1793862E (pt) * 2004-08-02 2011-04-08 Chiesi Farma Spa Processo para a preparação de um composto de inclusão de piroxicam:beta-ciclodextrina
FR2882556B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
RU2473544C2 (ru) 2007-05-30 2013-01-27 Инд-Свифт Лабораториз Лимитед Способ получения ивабрадина гидрохлорида и его полиморфных модификаций
CN101597261A (zh) 2008-06-06 2009-12-09 北京深蓝海生物医药科技有限公司 无定形盐酸伊伐布雷定
CN101463008A (zh) 2009-01-11 2009-06-24 山东鲁抗辰欣药业有限公司 盐酸伊伐布雷定无定型物及其制备方法
CN101559228B (zh) * 2009-06-01 2011-05-18 石药集团欧意药业有限公司 一种治疗高脂血症合并慢性稳定型心绞痛的药物组合物
SI2902384T1 (en) 2010-02-12 2018-03-30 Krka, D.D., Novo Mesto The form of ivabradine hydrochloride
CA2800442C (fr) 2010-06-14 2018-05-22 Ratiopharm Gmbh Composition pharmaceutique contenant de l'ivabradine a liberation modifiee
EP2589594A1 (fr) 2011-11-04 2013-05-08 Urquima S.A. Forme IV d'hydrochlorure d'ivabridine
WO2014161131A1 (fr) * 2013-04-01 2014-10-09 Arissa Pharma Préparation d'un complexe d'inclusion de méloxicam-β-cyclodextrine amorphe par l'intermédiaire d'un procédé de séchage par atomisation
CN103393611B (zh) * 2013-08-06 2015-08-19 南京正大天晴制药有限公司 一种盐酸伊伐布雷定片剂及其制备方法

Also Published As

Publication number Publication date
MX2016007682A (es) 2016-09-09
MX363389B (es) 2019-03-20
WO2015001133A1 (fr) 2015-01-08

Similar Documents

Publication Publication Date Title
ES2672472T3 (es) Composición farmacéutica que comprende ivabradina amorfa
US11007152B2 (en) Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
KR101359327B1 (ko) 리팍시민의 안정한 다형체 형태를 얻기 위한 폴리올의 용도
HRP20191104T1 (hr) Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
AU2005206063B2 (en) Method of preparing low-crystallinity oltipraz or amorphous oltipraz
BRPI0917807A2 (pt) formulação sólida estável de um polipeptídeo agonista de recepto gc-c adequada para administração oral
US20100016378A1 (en) Method of preventing dihydropyridine compound from degradation
US20170368048A1 (en) Pharmaceutical Composition Comprising Amorphous Lenalidomide
WO2016097011A1 (fr) Composition pharmaceutique comprenant de l'agomélatine amorphe
ES2471076T3 (es) Compuestos de inclusión de silodoxina-ciclodextrina
US11517569B2 (en) Vilazodone inclusion complexes, compositions and preparation thereof
US10471156B2 (en) Pharmaceutical composition comprising amorphous lenalidomide
KR100783286B1 (ko) 클로피도그렐 우선성 광학이성체의 유리염기를 함유하는고형의 약제학적 조성물
US9050326B2 (en) Amido derivatives-contained pharmaceutical composition
EP3079702B1 (fr) Composition pharmaceutique comprenant de l'ivabradine amorphe
US20080255231A1 (en) Polymorphs of rivastigmine hydrogentartrate
WO2020111089A1 (fr) Composition pharmaceutique
AU2013250251B2 (en) Encapsulated formulation
Kumar et al. Solid dispersions: An approach to enhance solubility of poorly soluble drugs
WO2020064188A1 (fr) Composition pharmaceutique comprenant des dispersions solides de cladribine amorphe et un excipient hydrosoluble pharmaceutiquement acceptable
Giri et al. Carriers used for the development of solid dispersion for poorly watersoluble drugs
KR100805675B1 (ko) 클로피도그렐 베실레이트를 포함하는 약학 조성물 및 그의제조방법
WO2008125134A1 (fr) Procédé de préparation d'adsorbats de périndopril-tert-butylamine
KR100673558B1 (ko) 사이클로덱스트린 또는 이의 유도체와 부틸프탈리드의 내포 착물, 이들의 제조 방법 및 용도
Samsodien Supramolecular derivatives of selected bioactive compounds: a physicochemical study